Novartis shares (NOVN.CH) are down around 10% today, the steepest decline in the STOXX Europe 600, following another disappointment involving one of the company’s key clinical programs. The Phase III HARBOR trial of the experimental drug del-desiran for the treatment of myotonic dystrophy type 1 failed to meet its primary endpoint. Today’s sell-off is particularly sharp because this marks the second significant clinical setback for Novartis within just a few days.
-
The HARBOR trial did not show a statistically significant improvement versus placebo in its primary endpoint, which measured hand-opening time as an indicator of myotonia severity. The study included around 150 patients treated for 54 weeks.
-
Novartis nevertheless highlighted that del-desiran showed signs of clinical activity across some secondary endpoints and exploratory analyses. The company intends to review the full dataset before deciding on the next steps for the therapy’s development.
-
The negative market reaction was amplified by earlier Phase III Lp(a)HORIZON results for pelacarsen. The drug failed to meet its primary objective of significantly reducing the risk of major cardiovascular events.
-
This means that two of the three key studies whose results Novartis has presented over the past week failed to meet their primary objectives, increasing market concerns over the pace at which the company can develop new sources of growth.
-
Despite the HARBOR setback, Novartis maintained its medium-term financial targets, including expectations for average annual sales growth of 5% to 6% between 2025 and 2030.
Novartis share price chart (NOVN.CH)
Novartis shares were down around 10% today to approximately CHF 114, reducing their year-to-date gain to less than 5%. If the decline holds, it would rank among the company’s worst single-day performances in decades and the weakest session since 2020. The company’s P/E ratio has cooled to around 20 times earnings.
Source: xStation5
Oil prices surge towards $100, as the yen rises, but Japan needs to tread carefully
Market Wrap: Far-right AfD wins in Germany, oil continues to rise (07.09.2026)
Economic Calendar: ECB decision, Oracle results, and US inflation - what to expect? (07.09.2026)
The Week Ahead
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.